Cite
Adjuvant palmitoylethanolamide therapy with risperidone improves negative symptoms in patients with schizophrenia: A randomized, double-blinded, placebo-controlled trial.
MLA
Salehi, Anahita, et al. “Adjuvant Palmitoylethanolamide Therapy with Risperidone Improves Negative Symptoms in Patients with Schizophrenia: A Randomized, Double-Blinded, Placebo-Controlled Trial.” Psychiatry Research, vol. 316, Oct. 2022, p. N.PAG. EBSCOhost, https://doi.org/10.1016/j.psychres.2022.114737.
APA
Salehi, A., Namaei, P., TaghaviZanjani, F., Bagheri, S., Moradi, K., Khodaei Ardakani, M.-R., & Akhondzadeh, S. (2022). Adjuvant palmitoylethanolamide therapy with risperidone improves negative symptoms in patients with schizophrenia: A randomized, double-blinded, placebo-controlled trial. Psychiatry Research, 316, N.PAG. https://doi.org/10.1016/j.psychres.2022.114737
Chicago
Salehi, Anahita, Parsa Namaei, Fateme TaghaviZanjani, Sayna Bagheri, Kamyar Moradi, Mohammad-Reza Khodaei Ardakani, and Shahin Akhondzadeh. 2022. “Adjuvant Palmitoylethanolamide Therapy with Risperidone Improves Negative Symptoms in Patients with Schizophrenia: A Randomized, Double-Blinded, Placebo-Controlled Trial.” Psychiatry Research 316 (October): N.PAG. doi:10.1016/j.psychres.2022.114737.